ReviewJournal of neurochemistry2026
Seed Amplification Assays for Parkinson's Disease: A Review of α-Synuclein Assays in Body Fluids and Tissues.
Review in Journal of neurochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- α-Synuclein Pathology in Idiopathic Normal Pressure Hydrocephalus: Evidence for Concomitant Synucleinopathy and Clinical Implications.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The pathological core of Parkinson's disease and related synucleinopathies involves the misfolding and aggregation of α-synuclein. Seed amplification assays (SAAs) have revolutionized the detection of pathological α-synuclein by enabling highly sensitive and specific identification of seeding activity. Cerebrospinal fluid (CSF)-based real-time quaking-induced conversion (RT-QuIC) demonstrates exceptional diagnostic accuracy for sporadic Parkinson's disease (PD) and dementia with Lewy bodies (DLB), with sensitivity reaching 93.3%-94.6% and pooled specificity of 94% (95% CI: 0.92-0.96), consistent with the meta-analysis of 21 core CSF studies. Alternative samples such as skin and intestinal tissues offer diagnostic accuracy up to 94.1%, providing less invasive options. These assays can distinguish conformational differences between Parkinson's disease/Lewy body dementia and multiple system atrophy (MSA), revealing potential for differential diagnosis through strain typing. In prodromal screening, SAAs show remarkable utility, with positivity rates exceeding 80% in idiopathic rapid eye movement sleep behavior disorder (iRBD) cohorts, indicating detection years before clinical diagnosis. Despite these advances, current limitations include small-sample sizes in many studies, insufficient multicenter validation, and lack of standardized protocols affecting interlaboratory consistency. Future efforts should focus on establishing standardized procedures, integrating digital biomarkers, and validating these technologies across diverse populations and disease stages to facilitate widespread clinical implementation. This study systematically evaluates the diagnostic performance of α-synuclein SAAs across biological samples, their role in differential diagnosis, and their potential in prodromal prediction and disease monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.